HSP60, HSP60 peptides and T cell vaccines for immunomodulation
    33.
    发明授权
    HSP60, HSP60 peptides and T cell vaccines for immunomodulation 失效
    HSP60,HSP60肽和用于免疫调节的T细胞疫苗

    公开(公告)号:US08691772B2

    公开(公告)日:2014-04-08

    申请号:US11813333

    申请日:2006-01-04

    IPC分类号: A61K38/00 C07K7/08

    摘要: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.

    摘要翻译: 本发明提供了人类热休克蛋白60(HSP60)的肽p277-位置437-460在调节免疫应答和炎性疾病方面的新用途。 本发明进一步提供HSP60和p277在治疗或预防肝病中的新用途。 本发明公开了治疗,预防或改善T细胞介导的炎症和自身免疫性疾病(包括肝脏疾病)的症状的方法,其包括向有需要的受试者施用包含有效量的选自以下的分子的组合物: HSP60,p277,其片段,类似物,同源物及其衍生物,以及编码其的核酸。 还公开了用于治疗或预防T细胞介导的病症的T细胞疫苗接种方法。

    T-CELL VACCINATION IN THE TREATMENT OF HIV INFECTION
    37.
    发明申请
    T-CELL VACCINATION IN THE TREATMENT OF HIV INFECTION 审中-公开
    T细胞疫苗治疗艾滋病毒感染

    公开(公告)号:US20100304483A1

    公开(公告)日:2010-12-02

    申请号:US12796971

    申请日:2010-06-09

    IPC分类号: C12N5/0783

    摘要: A method for the preparation of a T cell vaccine for the treatment of immunodeficient HIV-infected patients is described herein, based on the enrichment of autologous CD4-reactive CD8 T cells. Also described is a protocol for the implementation of T cell vaccination in immunodeficient HIV-infected, as well as a method of treatment, based on the T cell vaccine developed herein. Finally, kits for preparing the T cell vaccine as well as for implementing the protocol are also provided.

    摘要翻译: 基于自体CD4反应性CD8T细胞的富集,本文描述了用于制备用于治疗免疫缺陷型HIV感染患者的T细胞疫苗的方法。 还描述了用于在免疫缺陷型HIV感染中实施T细胞疫苗接种的方案,以及基于本文开发的T细胞疫苗的治疗方法。 最后,还提供了用于制备T细胞疫苗以及实施方案的试剂盒。

    Immunogenic compositions for induction of anti-tumor immunity
    39.
    发明授权
    Immunogenic compositions for induction of anti-tumor immunity 失效
    用于诱导抗肿瘤免疫的免疫原性组合物

    公开(公告)号:US07378092B2

    公开(公告)日:2008-05-27

    申请号:US11129359

    申请日:2005-05-16

    IPC分类号: A61K39/395 A61K39/00

    摘要: The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: (i) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (ii) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle. Preferably the immunogen is administered in the form of a pharmaceutical composition. Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.

    摘要翻译: 本发明涉及在哺乳动物中诱导抗肿瘤免疫和/或诱导对p53的免疫应答的方法。 所述方法包括向哺乳动物施用有效量的选自以下的至少一种免疫原:(i)基于抗p53mAb的重链或轻链的CDR的肽,所述肽能够引发 p53抗体; 和(ii)在合适的基因递送载体中编码抗p53mAb的可变(V)区的DNA分子。 优选地,免疫原以药物组合物的形式施用。 优选地,肽的长度为7至30个氨基酸残基,并且含有重链的CDR2或CDR3的序列,或抗-p53mAb的轻链的CDR3的序列。

    Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
    40.
    发明授权
    Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases 失效
    检测或监测T细胞介导的疾病治疗有效性的方法

    公开(公告)号:US06309847B1

    公开(公告)日:2001-10-30

    申请号:US08973782

    申请日:1998-07-22

    IPC分类号: A61K4900

    摘要: It has been discovered that treatment of an IDDM model with the p277 auto-antigen in a tolerogenic carrier induces a shift from a TH1 T cell response to a TH2 T cell response. The efficacy of proposed vaccines for any T cell mediated disease can be detected or monitored by measuring for such a TH1→TH2 T cell reponse shift.

    摘要翻译: 已经发现,在耐受性载体中用p277自身抗原治疗IDDM模型诱导从TH1T细胞应答向TH2T细胞应答的转移。 通过测量这种TH1> TH2T细胞反应位移可以检测或监测所提出的任何T细胞介导的疾病疫苗的功效。